{
  "input": {
    "mode": "score",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        }
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ciclosporin",
          "name": "Ciclosporin"
        }
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        }
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        }
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        }
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        }
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        }
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        }
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        }
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        }
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        }
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_risankizumab",
          "name": "Risankizumab"
        }
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "n_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ciclosporin",
          "type": "Drug",
          "label": "Ciclosporin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_risankizumab",
          "type": "Drug",
          "label": "Risankizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_gp_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_th17_pathway",
          "type": "Pathway",
          "label": "Th17 pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_immunomodulation",
          "type": "Pathway",
          "label": "Immunomodulation pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_inflammation",
          "type": "Phenotype",
          "label": "Inflammation",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_skin_flare",
          "type": "Phenotype",
          "label": "Skin Flare",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Ciclosporin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_ciclosporin",
          "type": "Drug",
          "label": "Ciclosporin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Guselkumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Risankizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_risankizumab",
          "type": "Drug",
          "label": "Risankizumab",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "n_acitretin",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知促发Th17细胞网络"
        },
        {
          "source": "n_ciclosporin",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "免疫调节作用支持"
        },
        {
          "source": "n_methotrexate",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过免疫抑制改善病症"
        },
        {
          "source": "n_ustekinumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "靶向IL-23，干预Th17反应"
        },
        {
          "source": "n_secukinumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接抑制IL-17"
        },
        {
          "source": "n_infliximab",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "TNF-α抑制剂，对应炎症"
        },
        {
          "source": "n_etanercept",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "也为TNF-α抑制剂"
        },
        {
          "source": "n_tildrakizumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "靶向IL-23，减轻症状"
        },
        {
          "source": "n_apremilast",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "磷酸二酯酶4抑制剂，有助于控制炎症"
        },
        {
          "source": "n_brodalumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向IL-17的单抗及其作用机制"
        },
        {
          "source": "n_guselkumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "靶向IL-23相关机制"
        },
        {
          "source": "n_risankizumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "针对IL-23的作用"
        },
        {
          "source": "n_th17_pathway",
          "target": "n_inflammation",
          "relation": "involved_in",
          "weight": 0.87,
          "agent": "Proponent",
          "rationale": "与炎症表型直接相关"
        },
        {
          "source": "n_inflammation",
          "target": "n_gp_psoriasis",
          "relation": "associated_with",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "炎症与广泛性脓疱型银屑病直接相关"
        },
        {
          "source": "n_immunomodulation",
          "target": "n_skin_flare",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "调节免疫反应对皮肤反应影响"
        },
        {
          "source": "n_skin_flare",
          "target": "n_gp_psoriasis",
          "relation": "associated_with",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "皮肤反应与疾病的临床表现一致"
        }
      ],
      "round_index": 3
    },
    "history": {
      "round": 3,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.78,
          "components": {
            "mechanism_fit": 0.9,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 3,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Acitretin 作用于 Th17 通路，与广泛性脓疱型银屑病相关的炎症机制吻合"
            ]
          },
          "confidence": "high"
        },
        {
          "hypothesis_id": "H2",
          "score": 0.83,
          "components": {
            "mechanism_fit": 0.85,
            "class_prior": 0.7,
            "pk_pd_feasibility": 0.75,
            "indication_plausibility": 0.75,
            "safety_risk": 0.25,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.02
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 3,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ciclosporin 的免疫调节作用与广泛性脓疱型银屑病的治疗相关"
            ]
          },
          "confidence": "high"
        },
        {
          "hypothesis_id": "H3",
          "score": 0.76,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.15,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.04
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate 通过免疫抑制改善广泛性脓疱型银屑病症状"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H4",
          "score": 0.8,
          "components": {
            "mechanism_fit": 0.9,
            "class_prior": 0.75,
            "pk_pd_feasibility": 0.75,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 0.9,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 3,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab 靶向 IL-23，干预 Th17 反应，与广泛性脓疱型银屑病相关"
            ]
          },
          "confidence": "high"
        },
        {
          "hypothesis_id": "H5",
          "score": 0.79,
          "components": {
            "mechanism_fit": 0.85,
            "class_prior": 0.75,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.75,
            "safety_risk": 0.15,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.03
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 3,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Secukinumab 直接抑制 IL-17，适用于广泛性脓疱型银屑病治疗"
            ]
          },
          "confidence": "high"
        },
        {
          "hypothesis_id": "H6",
          "score": 0.77,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.75,
            "pk_pd_feasibility": 0.75,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.02
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab 作为 TNF-α 抑制剂，减缓广泛性脓疱型银屑病的炎症反应"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H7",
          "score": 0.74,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.7,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.65,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.03
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept 在炎症控制方面可能有效，但与广泛性脓疱型银屑病的直接关联欠缺"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H8",
          "score": 0.75,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.65,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.15,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.03
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Tildrakizumab 的作用与 IL-23 的靶向一致，显示出对广泛性脓疱型银屑病的可能疗效"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H9",
          "score": 0.72,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.03
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Apremilast 通过磷酸二酯酶4抑制发挥免疫作用，但与疾病的直接联系需进一步研究"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H10",
          "score": 0.71,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.02
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Brodalumab 对 IL-17 的靶向作用显示出潜在效用，但整体证据相对较少"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H11",
          "score": 0.74,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.65,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.02
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Guselkumab 的 IL-23 靶点对广泛性脓疱型银屑病具有相关性，但证据量需加强"
            ]
          },
          "confidence": "medium"
        },
        {
          "hypothesis_id": "H12",
          "score": 0.7,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.03
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Risankizumab 作为 IL-23 抑制剂与广泛性脓疱型银屑病的治疗相关，但证据需进一步支持"
            ]
          },
          "confidence": "medium"
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "scoring_summary": [
      {
        "hypothesis_id": "H1",
        "score": 0.78,
        "components": {
          "mechanism_fit": 0.9,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.8,
          "safety_risk": 0.2,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 0.85,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Acitretin 作用于 Th17 通路，与广泛性脓疱型银屑病相关的炎症机制吻合"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H2",
        "score": 0.83,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.7,
          "pk_pd_feasibility": 0.75,
          "indication_plausibility": 0.75,
          "safety_risk": 0.25,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.85,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ciclosporin 的免疫调节作用与广泛性脓疱型银屑病的治疗相关"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H3",
        "score": 0.76,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.7,
          "safety_risk": 0.15,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.04
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate 通过免疫抑制改善广泛性脓疱型银屑病症状"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "score": 0.8,
        "components": {
          "mechanism_fit": 0.9,
          "class_prior": 0.75,
          "pk_pd_feasibility": 0.75,
          "indication_plausibility": 0.8,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 0.9,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab 靶向 IL-23，干预 Th17 反应，与广泛性脓疱型银屑病相关"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H5",
        "score": 0.79,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.75,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.75,
          "safety_risk": 0.15,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.85,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Secukinumab 直接抑制 IL-17，适用于广泛性脓疱型银屑病治疗"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H6",
        "score": 0.77,
        "components": {
          "mechanism_fit": 0.8,
          "class_prior": 0.75,
          "pk_pd_feasibility": 0.75,
          "indication_plausibility": 0.7,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab 作为 TNF-α 抑制剂，减缓广泛性脓疱型银屑病的炎症反应"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H7",
        "score": 0.74,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.7,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Etanercept 在炎症控制方面可能有效，但与广泛性脓疱型银屑病的直接关联欠缺"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H8",
        "score": 0.75,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.65,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.7,
          "safety_risk": 0.15,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Tildrakizumab 的作用与 IL-23 的靶向一致，显示出对广泛性脓疱型银屑病的可能疗效"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H9",
        "score": 0.72,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Apremilast 通过磷酸二酯酶4抑制发挥免疫作用，但与疾病的直接联系需进一步研究"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H10",
        "score": 0.71,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Brodalumab 对 IL-17 的靶向作用显示出潜在效用，但整体证据相对较少"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H11",
        "score": 0.74,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.65,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Guselkumab 的 IL-23 靶点对广泛性脓疱型银屑病具有相关性，但证据量需加强"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H12",
        "score": 0.7,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Risankizumab 作为 IL-23 抑制剂与广泛性脓疱型银屑病的治疗相关，但证据需进一步支持"
          ]
        },
        "confidence": "medium"
      }
    ],
    "ranking": [
      "H2",
      "H4",
      "H5",
      "H1",
      "H6",
      "H3",
      "H8",
      "H9",
      "H7",
      "H10",
      "H11",
      "H12"
    ],
    "delta_since_last_round": 0.05,
    "stop_decision": {
      "should_stop": false,
      "reasons": [
        "Δscore≥0.03"
      ]
    }
  }
}